Stock Track | Aurinia Pharmaceuticals Soars on Stellar Q3 Results and Strategic Restructuring

Stock Track11-07

Aurinia Pharmaceuticals (AUPH) stock surged over 7% in pre-market trading after the company reported impressive financial results for the third quarter of 2024 and announced a strategic restructuring plan.

The biopharmaceutical firm reported adjusted earnings per share of $0.10 for Q3 2024, marking a remarkable 900% beat over the analyst consensus estimate of $0.01. Aurinia's quarterly revenue of $67.8 million also significantly exceeded Wall Street's expectations of $57.69 million, growing at a robust 24% year-over-year.

Aurinia's strong performance was driven by continued momentum in sales of its lupus drug LUPKYNIS, with the company reiterating its 2024 net product revenue guidance range of $210 million to $220 million.

Furthermore, Aurinia unveiled a strategic restructuring plan to sharpen its focus on LUPKYNIS growth and the development of its pipeline candidate AUR200, a potential best-in-class therapy for autoimmune diseases. The restructuring, which includes a workforce reduction of approximately 45%, is expected to generate annualized cash-based operating expense savings of more than $40 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100014185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100014185","market":"us","top_or_hot":-1,"title":"Stock Track | Aurinia Pharmaceuticals Soars on Stellar Q3 Results and Strategic Restructuring","media":"Stock Track","content":"<p>Aurinia Pharmaceuticals (AUPH) stock surged over 7% in pre-market trading after the company reported impressive financial results for the third quarter of 2024 and announced a strategic restructuring plan.</p>\n\n<p>The biopharmaceutical firm reported adjusted earnings per share of $0.10 for Q3 2024, marking a remarkable 900% beat over the analyst consensus estimate of $0.01. Aurinia's quarterly revenue of $67.8 million also significantly exceeded Wall Street's expectations of $57.69 million, growing at a robust 24% year-over-year.</p>\n\n<p>Aurinia's strong performance was driven by continued momentum in sales of its lupus drug LUPKYNIS, with the company reiterating its 2024 net product revenue guidance range of $210 million to $220 million.</p>\n\n<p>Furthermore, Aurinia unveiled a strategic restructuring plan to sharpen its focus on LUPKYNIS growth and the development of its pipeline candidate AUR200, a potential best-in-class therapy for autoimmune diseases. The restructuring, which includes a workforce reduction of approximately 45%, is expected to generate annualized cash-based operating expense savings of more than $40 million.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Aurinia Pharmaceuticals Soars on Stellar Q3 Results and Strategic Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Aurinia Pharmaceuticals Soars on Stellar Q3 Results and Strategic Restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 22:49 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aurinia Pharmaceuticals (AUPH) stock surged over 7% in pre-market trading after the company reported impressive financial results for the third quarter of 2024 and announced a strategic restructuring ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AUPH","symbol_name":"Aurinia Pharmaceuticals Inc","start_time":0,"source_url":"","article_id":"1100014185","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100014185","pubTimestamp":1730990969,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Aurinia Pharmaceuticals  stock surged over 7% in pre-market trading after the company reported impressive financial results for the third quarter of 2024 and announced a strategic restructuring plan.The biopharmaceutical firm reported adjusted earnings per share of $0.10 for Q3 2024, marking a remarkable 900% beat over the analyst consensus estimate of $0.01. Aurinia's quarterly revenue of $67.8 million also significantly exceeded Wall Street's expectations of $57.69 million, growing at a robust","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AUPH":"Aurinia Pharmaceuticals Inc"},"translate_title":"股票赛道Aurinia Pharmaceuticals因出色的第三季度业绩和战略重组而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUPH":1},"content_text":"Aurinia Pharmaceuticals (AUPH) stock surged over 7% in pre-market trading after the company reported impressive financial results for the third quarter of 2024 and announced a strategic restructuring plan.\nThe biopharmaceutical firm reported adjusted earnings per share of $0.10 for Q3 2024, marking a remarkable 900% beat over the analyst consensus estimate of $0.01. Aurinia's quarterly revenue of $67.8 million also significantly exceeded Wall Street's expectations of $57.69 million, growing at a robust 24% year-over-year.\nAurinia's strong performance was driven by continued momentum in sales of its lupus drug LUPKYNIS, with the company reiterating its 2024 net product revenue guidance range of $210 million to $220 million.\nFurthermore, Aurinia unveiled a strategic restructuring plan to sharpen its focus on LUPKYNIS growth and the development of its pipeline candidate AUR200, a potential best-in-class therapy for autoimmune diseases. The restructuring, which includes a workforce reduction of approximately 45%, is expected to generate annualized cash-based operating expense savings of more than $40 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100014185"}